Brain Tumor Surgery in India
Get Brain Tumor Surgery at internationally accredited (JCI/NABH) Indian hospitals at a fraction of Western costs, with end-to-end international patient support — visa, travel, stay, and follow-up care.
Brain Tumor Surgery in UAE
Brain Tumor Surgery at leading UAE hospitals in Dubai and Abu Dhabi — world-class care closer to home, visa-free entry for many nationalities, international specialists, and modern facilities.
Overview
Brain tumor surgery encompasses a spectrum of neurosurgical interventions—from craniotomy and endoscopic resection to stereotactic radiosurgery—designed to remove, debulk, or ablate benign and malignant intracranial neoplasms, with gross total resection achieved in 70–90% of eligible cases depending on tumor grade, location, and histology. Patients traveling through GAF Healthcare gain access to JCI- and NABH-accredited neurosurgical centers in India and JCI- and DHA-accredited hospitals in Dubai and Abu Dhabi, where multidisciplinary tumor boards, intraoperative MRI (iMRI), fluorescence-guided surgery (5-ALA), and awake craniotomy protocols deliver outcomes benchmarked against leading Western institutions—at a fraction of the cost. India offers the most competitive pricing in Asia while the UAE provides ultra-premium facilities with seamless connectivity for patients from the Gulf, Africa, and Europe.
Hospital Stay: 7–14 days (ICU: 1–3 days, ward: 6–11 days; varies by tumor grade and surgical approach) • Total Stay in Country (Fit-to-Fly): 4–8 weeks (short-haul up to 4 hours may be cleared at 3–4 weeks post-op with neurosurgeon approval; long-haul intercontinental travel typically requires 6–8 weeks and a normal post-operative MRI) • Success Rate: 75–92% gross total or near-total resection rate for surgically accessible tumors (WHO Grade I–II); 5-year survival for glioblastoma with surgery + temozolomide + radiotherapy: 10–15%; meningioma resection cure rate (Simpson Grade I): >90%
What Is It?
A brain tumor is an abnormal proliferation of cells within the cranial vault—either primary (originating from glial, meningeal, or neural cells) or metastatic (seeded from lung, breast, colorectal, renal, or melanoma primaries). Primary brain tumors are classified by the WHO 2021 CNS classification system, which integrates histology with molecular markers such as IDH1/IDH2 mutation status, MGMT promoter methylation, 1p/19q co-deletion, TERT promoter mutation, and EGFR amplification. These markers are now mandatory for surgical planning and adjuvant therapy decisions. The tumor's mass effect—cerebral edema, midline shift, herniation, and hydrocephalus—produces the clinical syndrome of raised intracranial pressure (ICP), focal neurological deficits, seizures, and cognitive change.
The physiological consequences of an untreated or inadequately managed brain tumor extend beyond the lesion itself. Peritumoral edema driven by vascular endothelial growth factor (VEGF) disrupts the blood-brain barrier, causing progressive neurological deterioration. Obstructive hydrocephalus from posterior fossa or intraventricular tumors can produce a neurosurgical emergency requiring urgent ventriculostomy or ventriculoperitoneal (VP) shunting. Corticosteroids (dexamethasone 4–16 mg/day) are used perioperatively to reduce edema, while antiepileptic drugs (levetiracetam is preferred) are administered prophylactically in supratentorial lesions.
The modern standard of care for brain tumors is delivered by a multidisciplinary neuro-oncology team comprising neurosurgeons, neuroradiologists, neuropathologists, radiation oncologists, and medical oncologists. Surgery remains the cornerstone for tissue diagnosis, ICP relief, and cytoreduction. Maximum safe resection—guided by functional MRI (fMRI), diffusion tensor imaging (DTI) tractography, intraoperative neurophysiological monitoring (IONM), and 5-ALA fluorescence—is the primary surgical objective. Adjuvant therapy is tailored by molecular profile: temozolomide chemotherapy for IDH-mutant and MGMT-methylated gliomas, bevacizumab for recurrent glioblastoma, targeted BRAF inhibitors (dabrafenib + trametinib) for BRAF V600E-mutant tumors, and immunotherapy (pembrolizumab) for mismatch repair-deficient CNS tumors.
Candidates
• WHO Performance Status (ECOG 0–2) indicating adequate functional reserve for general anesthesia and craniotomy
• Radiologically confirmed intracranial mass on contrast-enhanced MRI Brain (1.5T or 3T with gadolinium) with evidence of mass effect, ring enhancement, or progressive growth
• Surgical accessibility confirmed by neurovascular mapping: tumors located in non-eloquent cortex, or in eloquent areas where awake craniotomy can preserve function
• Age typically 18–75 years; pediatric brain tumors (medulloblastoma, ependymoma, DIPG) assessed separately by pediatric neurosurgery board
• Histological diagnosis required: tissue biopsy (stereotactic or open) is mandatory prior to adjuvant therapy; liquid biopsy (CSF ctDNA) emerging as adjunct
• Required pre-operative diagnostics: Contrast-Enhanced MRI Brain and Spine (3T preferred), MR Spectroscopy, functional MRI (fMRI) for eloquent cortex mapping, Diffusion Tensor Imaging (DTI) for white matter tractography, PET-CT with FDG or FET-PET for metabolic activity grading and metastatic workup, CT Angiography or DSA for highly vascular tumors (meningioma, hemangioblastoma), Neuropsychological assessment, Complete blood count, coagulation profile (PT/INR/aPTT), comprehensive metabolic panel, and cardiac evaluation (ECG, ECHO) for patients over 50 or with cardiac history
• Molecular tumor profiling: IDH1/IDH2, MGMT methylation, EGFR, 1p/19q, TERT promoter, and next-generation sequencing (NGS) panel recommended for all WHO Grade II–IV gliomas
• CONTRAINDICATIONS: Karnofsky Performance Score (KPS) <50 indicating inability to tolerate surgery; deeply seated eloquent tumors with unacceptable neurological deficit risk (relative contraindication—stereotactic biopsy or radiosurgery considered); active systemic infection or sepsis; uncorrected coagulopathy; leptomeningeal carcinomatosis without dominant resectable lesion; patient refusal of blood products where required
Procedure
SURGICAL APPROACHES:
• Craniotomy with Microsurgical Resection: The gold standard for most supratentorial and posterior fossa tumors. A bone flap is elevated, the dura opened, and the tumor resected under high-magnification operative microscopy. Intraoperative MRI (iMRI, Siemens MAGNETOM) allows real-time assessment of resection completeness, enabling surgeons to re-operate within the same session if residual tumor is detected—increasing gross total resection (GTR) rates by 20–30%.
• 5-Aminolevulinic Acid (5-ALA) Fluorescence-Guided Surgery: Patients ingest 5-ALA 3 hours pre-operatively; malignant glioma cells selectively accumulate protoporphyrin IX, which fluoresces pink-violet under a BLUE 400 surgical microscope. This technique significantly increases GTR rates for glioblastoma (65% vs. 36% in landmark Stummer et al. trial) and is standard of care at leading Indian and UAE neurosurgical centers.
• Awake Craniotomy with Intraoperative Brain Mapping: For tumors in or adjacent to eloquent cortex (Broca's area, Wernicke's area, primary motor/sensory cortex), the patient is kept awake during resection. Real-time cortical and subcortical stimulation mapping (direct electrical stimulation, DES) identifies functional boundaries, maximizing resection while preserving language, motor, and cognitive function. Neuropsychologists, speech therapists, and specially trained anesthesiologists (asleep-awake-asleep technique) are integral to the team.
• Endoscopic Brain Surgery: Fully endoscopic or endoscope-assisted approaches are used for intraventricular tumors (colloid cysts, ependymomas, subependymal giant cell astrocytomas), pituitary adenomas (transsphenoidal endoscopic resection via the nostril with no external incision), and posterior fossa tumors. Key-hole craniotomies (supraorbital, retrosigmoid) minimize brain retraction and reduce hospital stay.
• Stereotactic Biopsy: For deep-seated or eloquent lesions not amenable to open resection, frame-based (Leksell) or frameless (Neuronavigation O-arm/iMRI-guided) stereotactic biopsy provides tissue diagnosis with sub-millimeter accuracy and <1% mortality risk.
• Neuronavigation (BrainLab/Medtronic StealthStation): Pre-operative imaging (MRI + DTI + fMRI) is co-registered to the patient's anatomy intraoperatively, providing GPS-like surgical navigation that reduces the risk of inadvertent eloquent cortex or critical white matter tract injury.
• Intraoperative Neurophysiological Monitoring (IONM): Continuous monitoring of motor evoked potentials (MEPs), somatosensory evoked potentials (SSEPs), and electrocorticography (ECoG) provides real-time feedback on cortical and subcortical function throughout resection, serving as an early warning system for neurological injury.
RADIOSURGERY (NON-INVASIVE):
• Stereotactic Radiosurgery (SRS): Gamma Knife (Elekta Leksell Gamma Knife Icon), CyberKnife (Accuray), or LINAC-based SRS delivers ablative radiation doses (12–24 Gy in 1–5 fractions) with sub-millimeter accuracy to residual tumor, recurrent lesions, or surgical contraindicated patients. Indicated for brain metastases ≤4 lesions, acoustic neuromas, meningiomas (Simpson Grade III–IV), recurrent AVM, and post-surgical residual glioma.
• Laser Interstitial Thermal Therapy (LITT): A minimally invasive technique (NeuroBlate/Monteris system) where a laser probe is stereotactically placed into a deep-seated or radiation-recurrent tumor and thermal ablation destroys tumor cells under real-time MRI thermometry. Particularly useful for radiation necrosis, recurrent glioblastoma, and thalamic or basal ganglia tumors.
ADJUVANT ONCOLOGICAL THERAPY (Post-Surgical):
• Stupp Protocol (Glioblastoma, IDH-wildtype WHO Grade IV): Concurrent temozolomide 75 mg/m²/day during radiotherapy (60 Gy in 30 fractions), followed by 6 cycles of adjuvant temozolomide 150–200 mg/m² (Days 1–5 of 28-day cycle). MGMT promoter methylation is predictive of temozolomide benefit.
• TTFields (Tumor Treating Fields, Optune device): Alternating electric fields delivered via transducer arrays applied to the scalp, FDA-approved for newly diagnosed and recurrent glioblastoma, extending median survival when added to standard chemoradiation.
• Bevacizumab (anti-VEGF): For recurrent glioblastoma, often combined with lomustine or temozolomide.
• Targeted Therapy: BRAF inhibitors (dabrafenib + trametinib) for BRAF V600E-mutant gliomas and pediatric low-grade gliomas; larotrectinib/entrectinib for NTRK fusion-positive CNS tumors; IDH inhibitors (ivosidenib, vorasidenib) for IDH-mutant low-grade gliomas—vorasidenib FDA-approved 2024.
• Immunotherapy: Pembrolizumab and nivolumab for MSI-high or TMB-high CNS tumors; ongoing trials for glioblastoma.
Cost of Brain Tumor Surgery: India vs. UAE
The cost of brain tumor surgery varies significantly depending on tumor grade, surgical complexity, technology employed (iMRI, 5-ALA, awake craniotomy), duration of ICU stay, and adjuvant therapy required. Both India and the UAE offer internationally benchmarked neurosurgical care at costs substantially below the United States ($80,000–$150,000) or the United Kingdom (£60,000–£100,000). India's cost advantage—driven by lower operational costs, high surgeon volume, and currency differential—makes it one of the world's most sought-after destinations for neurosurgical care, while the UAE offers a premium, luxury-grade experience with maximum convenience for Gulf-region and European patients.
| Destination | Estimated Cost (USD) | Key Advantage |
|---|---|---|
| India | $5,000 – $18,000 | ~56% less than the UAE |
| UAE (Dubai/Abu Dhabi) | $12,000 – $40,000 | Premium care, JCI/DHA accredited |
Estimates typically include surgery, hospital stay, and standard medications. Contact us for a personalised quote.
Recovery & Aftercare
PRE-OPERATIVE PHASE (Days -14 to 0):
Step 1 — Remote Case Review (Before Travel): Patient submits MRI Brain (DICOM files), biopsy reports (if available), molecular pathology, and clinical history to GAF Healthcare's neurosurgical panel. A senior neurosurgeon reviews the case within 48–72 hours and issues a written surgical opinion including recommended approach, estimated duration, expected outcomes, and a provisional cost estimate. Video consultation is arranged if required.
Step 2 — Travel and Pre-Admission (Days -3 to -1): Patient and one attendant arrive in India or the UAE. GAF Healthcare coordinator manages airport pickup, hotel accommodation near the hospital, and hospital registration. Pre-operative workup is completed: contrast MRI Brain ± Spine, fMRI, DTI, PET-CT, neuropsychological baseline, blood work, cardiac clearance, and anesthesiology pre-assessment. Dexamethasone is initiated if significant edema is present. Levetiracetam is started for seizure prophylaxis in supratentorial tumors.
Step 3 — Pre-Operative Planning Conference: The multidisciplinary tumor board (neurosurgeon, neuroradiologist, neuro-oncologist, radiation oncologist, neuropathologist) reviews all imaging and plans the surgical strategy: craniotomy vs. endoscopy vs. biopsy; awake vs. asleep; 5-ALA fluorescence protocol; IONM modalities required. Surgical plan is uploaded to the BrainLab/Stealthstation navigation system.
THE PROCEDURE (Day 0, Duration: 4–12 hours depending on tumor complexity):
Step 4 — Anesthesia and Positioning: General anesthesia (or asleep-awake-asleep for awake craniotomy). Patient positioned in a Mayfield pin-head fixation device. Neuronavigation system registered to patient anatomy using intraoperative surface scanning or fiducial markers.
Step 5 — Craniotomy: Scalp incision, burr holes placed, and bone flap elevated. Dura opened in curvilinear fashion. Cortical mapping performed (direct electrical stimulation or awake mapping). Surgical approach corridor planned to minimize retraction of normal brain.
Step 6 — Tumor Resection: Microsurgical resection under operative microscope with 5-ALA fluorescence guidance. IONM team monitors MEPs and SSEPs continuously. Intraoperative ultrasound or iMRI confirms degree of resection. Hemostasis achieved with bipolar cautery, hemostatic agents (Surgicel, FloSeal). Dura closed watertight (synthetic dural substitute if needed). Bone flap replaced and fixed with titanium plates. Scalp closed in layers.
Step 7 — Immediate Post-Operative Care (ICU, Days 1–3): Patient transferred to Neuro-ICU for continuous neurological monitoring (GCS, pupillary responses, ICP monitoring if indicated). CT Brain performed within 6 hours post-operatively to exclude hemorrhage or edema. Dexamethasone continued and tapered. Levetiracetam continued. Early post-operative MRI (24–72 hours) to assess resection extent.
POST-OPERATIVE RECOVERY (Days 3–14, Ward Phase):
Step 8 — Neurological Rehabilitation Initiation: Physical therapy, occupational therapy, and speech therapy begin as early as Day 1–2. Swallowing assessment for posterior fossa surgeries. DVT prophylaxis (LMWH, compression stockings) initiated 24–48 hours post-op.
Step 9 — Wound Care and Suture Removal: Surgical staples or sutures removed at Day 10–14. Wound assessed for CSF leak, infection, or dehiscence.
Step 10 — Adjuvant Therapy Planning: Molecular pathology results (IDH, MGMT, 1p/19q) available within 7–14 days. Multidisciplinary team meets to finalize adjuvant chemoradiation schedule. Radiation planning CT and simulation performed if radiotherapy is to be delivered locally in India or UAE before departure.
Step 11 — Discharge and Post-Operative MRI: Patient discharged with detailed clinical summary, molecular pathology report, surgical operative note, and adjuvant therapy recommendation letter. First post-operative MRI (contrast-enhanced) performed at 2–4 weeks post-op as baseline for surveillance.
FIT-TO-FLY AND LONG-TERM MILESTONES:
• 3–4 weeks post-op: Cleared for short-haul flights (<4 hours) if wound healed, neurologically stable, no VTE, and neurosurgeon approval obtained.
• 6–8 weeks post-op: Cleared for long-haul intercontinental travel; adjuvant temozolomide cycles can continue in home country with the treatment protocol provided by GAF Healthcare's oncology team.
• 3 months: Follow-up MRI (pseudo-progression vs. true progression assessment using MR Perfusion and Spectroscopy).
• 6 months and annually: Surveillance MRI; neuropsychological follow-up; quality of life assessment.
Risks & Considerations
Brain tumor surgery carries procedure-specific risks that patients must understand before providing informed consent. Neurological deficits—including new or worsened motor weakness, speech disturbance (aphasia or dysarthria), visual field defects, or cognitive change—occur in 10–25% of cases involving tumors in or adjacent to eloquent cortex; the majority are transient, resolving within 6–12 weeks with rehabilitation, but a minority (5–8%) may be permanent. Cerebral edema peaking at 48–72 hours post-operatively can cause clinical deterioration requiring aggressive corticosteroid therapy or, rarely, surgical decompression. Intracranial hemorrhage at the resection cavity occurs in 2–5% of cases and may require urgent re-exploration. Infection—surgical site infection, meningitis, or cerebral abscess—occurs in 1–3% of cases; risk is higher with prolonged surgery, CSF leak, or external ventricular drainage. Cerebrospinal fluid (CSF) leak manifesting as rhinorrhea, otorrhea, or wound pseudomeningocele occurs in 3–7% of posterior fossa and skull base surgeries; most resolve with lumbar drainage but may require surgical repair. Venous thromboembolism (DVT and pulmonary embolism) is a significant risk in neurosurgical patients due to immobility and pro-coagulant tumor microenvironment; routine prophylaxis with low-molecular-weight heparin and mechanical compression devices is standard. Seizures, new-onset or exacerbated, affect 10–30% of supratentorial tumor patients perioperatively; antiepileptic therapy is continued for a minimum of 3–12 months. For posterior fossa tumors, cranial nerve palsies (particularly CN V, VII, VIII, IX, X) and cerebellar mutism (in pediatric patients) are recognized complications. General anesthesia risks include pulmonary complications, deep vein thrombosis, and cardiovascular events, which are mitigated by thorough pre-operative cardiac and pulmonary assessment. Patients should be counseled that gross total resection does not equal cure for high-grade gliomas; recurrence remains the rule for glioblastoma despite optimal surgery and chemoradiation, and ongoing surveillance MRI is non-negotiable.
Top Hospitals for Brain Tumor Surgery
The following JCI and NABH-accredited hospitals are among the most experienced in specialist care, with dedicated teams and high-volume programmes.
Manipal Hospitals
Bengaluru, India
Manipal Hospitals Dwarka
New Delhi, India
Burjeel Hospital for Advanced Surgery Dubai
Dubai, UAE
Kings College Hospital Dubai
Dubai, UAE
Top Doctors for Brain Tumor Surgery
Internationally trained specialists in Neurology. Review their profiles, compare experience, and connect directly through GAF Healthcare.
Dr. Anuvrat Sinha
MBBS (with Distinction in Pharmacology), MS (General Surgery), MCh (Neurosurgery)
Neurosurgeon
Artemis Hospital, Gurugram, India
12+ Yearsof experience
Dr. Anuvrat Sinha is a Consultant Neurosurgeon at Artemis Hospital, Gurugram, with over 12 years of medical experience. He specialises in complex brain tumor surgeries — including glioma and meningioma — as well as endoscopic brain procedures, craniotomies, and a wide range of spinal surgeries. Patients and families often describe him as someone who takes the time to explain a difficult diagnosis in plain language, which matters enormously when the stakes… Read more
Dr. Arul K
MBBS, MS, FRCS (Ed) — Fellow of the Royal College of Surgeons of Edinburgh, Neurosurgery Board Certification
Neurosurgeon
Gleneagles HealthCity Chennai, Chennai, India
27+ Yearsof experience
Dr. Arul K is a seasoned neurosurgeon based in Chennai with over 27 years of experience caring for patients with complex brain and spine conditions. Currently serving as Associate Consultant at Gleneagles HealthCity Chennai, he has built a reputation for handling some of the most challenging neurosurgical cases — from skull base tumours and arteriovenous malformations to delicate endoscopic brain procedures. His patients and their families often describe… Read more
Dr. Deepak Arisikere Nataraju
MBBS, MS (General Surgery), M.Ch (Neurosurgery)
Neurosurgeon
Medicover Hospital, Whitefield, Bengaluru, India
20+ Yearsof experience
Dr. Deepak Arisikere Nataraju is a Senior Consultant Neurosurgeon at Medicover Hospitals, Whitefield, Bengaluru, with over two decades of experience in treating complex conditions of the brain, spine, and nervous system. He is widely recognized in the region for his work in minimally invasive spine surgery, endoscopic brain surgery, and skull base procedures — areas where precision and experience make a real difference to patient outcomes. Dr. Deepak… Read more
Dr. Karanjit Singh Narang
M.Ch. (Neurosurgery), M.S. (General Surgery), MBBS
Neurosurgeon
Medanta – The Medicity, Gurugram, India
25+ Yearsof experience
Dr. Karanjit Singh Narang is one of India's most experienced neurosurgeons, serving as Senior Director of Neurosurgery at Medanta – The Medicity in Gurugram. With more than 25 years in the field, he has built a reputation for handling some of the most complex brain and spine conditions — including brain tumors, gliomas, meningiomas, and skull base tumors — using minimally invasive and image-guided techniques that put patient safety first. Dr. Narang… Read more
Dr. Krishna Kumar Choudhary
MS (Surgery), DNB (Neurosurgery), ECFMG Certification, Fellowship in Neurosurgery
Neurosurgeon
Indian Spinal Injuries Centre, New Delhi, India
27+ Yearsof experience
Dr. Krishna Kumar Choudhary is one of India's most experienced neurosurgeons, with over 27 years dedicated entirely to brain and spine surgery. He serves as Director and Chief of Neurosurgery at the Indian Spinal Injuries Centre in New Delhi — a role that reflects both his seniority and the depth of trust his peers and patients place in him. Over the decades, he has built a reputation for taking on complex neurosurgical cases that require not just… Read more
Patient Success Story
Frequently Asked Questions — Brain Tumor Surgery
The cost of brain tumor surgery in India ranges from approximately $5,000 to $18,000 USD, making it one of the most cost-effective destinations globally for high-quality neurosurgical care. This range covers craniotomy with microsurgical resection, intraoperative neurophysiological monitoring, a 7–14 day hospital stay including ICU, standard postoperative medications, and molecular pathology reporting. Advanced add-ons such as intraoperative MRI (iMRI) or 5-ALA fluorescence guidance may add $1,000–$3,000 to the total. In the UAE (Dubai or Abu Dhabi), the same procedures cost between $12,000 and $40,000 USD—reflecting the premium infrastructure, luxury hospital environment, and higher operational costs in the Gulf. Both destinations charge significantly less than the United States ($80,000–$150,000) or the United Kingdom (£60,000–£100,000) for equivalent procedures. GAF Healthcare provides fully itemized cost estimates before travel so there are no hidden charges. Note that stereotactic radiosurgery (Gamma Knife or CyberKnife), if required as a standalone or adjuvant procedure, is priced separately at $4,000–$8,000 in India and $8,000–$18,000 in the UAE.
The minimum safe in-country stay after brain tumor surgery is typically 4–8 weeks, depending on the surgical complexity, your neurological recovery, and your destination (short-haul vs. long-haul flight). For the first 7–14 days, you will be in hospital recovering in the ICU and then the ward. After discharge, you will need to remain near the treating hospital for wound review, suture removal (Day 10–14), and a critical post-operative MRI at 2–4 weeks to assess resection extent and rule out early complications such as pseudo-progression, residual tumor, or hydrocephalus. Clearance for flight is given by your neurosurgeon based on three criteria: wound integrity, neurological stability, and absence of active venous thromboembolism (VTE) risk. Short-haul flights under 4 hours may be cleared as early as 3–4 weeks post-operatively for uncomplicated cases. Long-haul intercontinental flights—particularly those over 6–8 hours—require a minimum of 6–8 weeks post-operatively because prolonged immobility significantly increases DVT and pulmonary embolism risk, and cabin pressure changes can exacerbate cerebral edema in the early post-operative period. Patients who develop post-operative complications such as CSF leak, infection, or significant neurological deficit may require a longer in-country stay of up to 10–12 weeks. GAF Healthcare arranges comfortable serviced apartment accommodation for this recovery period.
Success rates in brain tumor surgery depend heavily on tumor type, WHO grade, molecular profile, location, and the extent of resection achieved. For benign tumors such as meningiomas (WHO Grade I), complete surgical resection (Simpson Grade I) is curative in over 90% of cases with a recurrence rate below 5% at 10 years. For vestibular schwannomas (acoustic neuromas), surgical resection or Gamma Knife radiosurgery achieves tumor control in 90–95% of cases. For WHO Grade II (low-grade gliomas, IDH-mutant), the 10-year overall survival exceeds 70% with maximum safe resection plus surveillance or adjuvant therapy. For glioblastoma (WHO Grade IV, IDH-wildtype)—the most aggressive primary brain tumor—the Stupp protocol (surgery + temozolomide + radiotherapy) yields a median overall survival of 14–16 months, with MGMT promoter-methylated patients achieving 21–24 months median survival; approximately 10–15% of patients survive beyond 5 years, and this subset is disproportionately represented among patients receiving molecular-guided therapy at high-volume centers. For single brain metastases, surgical resection combined with stereotactic radiosurgery (SRS) achieves local control in 85–95% of cases and significantly improves quality of life and survival over whole-brain radiotherapy alone. It is important to note that 'success' in neuro-oncology encompasses not only tumor control but also preservation of neurological function and quality of life—outcomes that are maximized by the high-volume, technology-equipped surgical teams available through GAF Healthcare's partner hospitals in India and the UAE.
Why Plan Your Treatment Through Gaf Healthcare?
GAF Healthcare provides comprehensive end-to-end non-medical coordination for brain tumor surgery patients traveling to India or the UAE, ensuring that patients and their families can focus entirely on treatment and recovery.
INDIA — VISA AND ENTRY: GAF Healthcare's dedicated visa team assists patients in applying for the Indian e-Medical Visa (e-MV), which is specifically designed for patients traveling for medical treatment and covers one accompanying attendant on an e-Medical Attendant Visa. The e-Medical Visa permits a stay of up to 60 days, extendable within India, and allows multiple entries. Required documents—hospital invitation letter, GAF Healthcare's registered medical institution letter, passport copies, and travel itinerary—are prepared and submitted by our coordinators. Visa approval is typically granted within 3–5 working days.
UAE (DUBAI / ABU DHABI) — VISA AND ENTRY: Passport holders from 49+ countries, including EU, UK, US, Canada, Australia, and GCC nationals, enjoy visa-free access to the UAE or receive a visa on arrival. For nationalities requiring prior visa, GAF Healthcare facilitates the UAE Medical Visa application process through the General Directorate of Residency and Foreigners Affairs (GDRFA), with the hospital's formal treatment confirmation serving as the supporting document. Visa-on-arrival extensions up to 30 days are available for medical cases and are coordinated by our UAE case managers.
AIRPORT TRANSFERS AND LOCAL TRANSPORT: Private ambulance or wheelchair-accessible vehicle transfers are arranged for all arrival and departure journeys. For patients with active neurological deficits—hemiparesis, aphasia, or altered consciousness—medically supervised transfers with a paramedic attendant can be arranged between airport and hospital.
DEDICATED PATIENT COORDINATORS AND TRANSLATORS: Each patient is assigned a dedicated GAF Healthcare case manager who remains the single point of contact throughout the treatment journey. Professional medical interpreters are available in Arabic, Russian, French, Swahili, Bengali, and other languages for patient consultations, consent discussions, and discharge briefings. Interpretation is provided in person for surgical consent and telephonically for daily clinical updates.
ACCOMMODATION FOR ATTENDANTS: GAF Healthcare partners with hospitals offering in-room attendant cots or attached attendant rooms at no additional charge during the ICU and acute ward phase. For the post-discharge recovery period (Weeks 2–8), we arrange serviced apartments or partner hotels within 1–2 km of the treating hospital, offering medical-grade hygiene standards, dietary meal options (including culturally appropriate and halal menus), and 24-hour concierge support. Monthly rental packages are negotiated at preferential rates for GAF Healthcare patients.
TELEMEDICINE FOLLOW-UP AFTER RETURN HOME: Post-departure follow-up consultations with the treating neurosurgeon and neuro-oncologist are conducted via secure video link at 4 weeks, 3 months, and 6 months. MRI and laboratory reports from the patient's home country are reviewed remotely, and adjuvant therapy guidance is communicated to the patient's local oncologist in a structured clinical handover letter.